We are turning this account into a fully automated page.
To learn more about what’s going on at Immunity, please follow us on LinkedIn! linkedin.com/company/immuni…
CD8+ T cells in the cancer-immunity cycle: CD8+ T cells are “end effectors” of cancer immunity. Wherry, Kaech, Giles, & Globig review the current understanding of CD8+ T cell differentiation and function in cancer, discussing recent advances within a four-signal framework that
2/ The study was eventually accepted by a niche publication called @ImmunityCP." Niche publication, seriously?? 🤣 It's a journal mere mortal scientists dream of publishing in...what a biting comment! @Nature and @ScienceMagazine have repeatedly passed on future Nobel work.
Special issue on "The cancer-immunity cycle," a concept first introduced by Mellman & Chen in 2013 that provided a framework to understand anti-cancer immunity | Seven articles discussing progress & advances in the field & highlighting key challenges #cancerimmunitycycle
New issue online! In honor of the #NobelPrize2023 awarded to @kkariko & @WeissmanLab, an essay from Brian Brown, Anthony Fauci, @BelkaidLab & @MiriamMerad tells the story of their transformative discovery: the successes and challenges, and the perseverance and vision that were
Online now: Transcription factor Ikzf1 associates with Foxp3 to repress gene expression in Treg cells and limit autoimmunity and anti-tumor immunity dlvr.it/TBZklH